Mr. Andre Larente reports

DIAGNOS SECURES EXCLUSIVE DISTRIBUTION AGREEMENT FOR CANADA WITH ESSILORLUXOTTICA, A GLOBAL LEADER IN VISION CARE

Diagnos Inc. has arranged a groundbreaking strategic partnership with EssilorLuxottica, a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses. This exclusive distribution agreement for Canada, signed on Dc. 6, 2023, signals a monumental leap for Diagnos, solidifying its standing as a premier provider of cutting-edge retinal analysis technology.

Diagnos's AI-powered (artificial intelligence) retinal image analysis technology has gained widespread acclaim in numerous countries, delivering invaluable benefits to eye health. This state-of-the-art solution facilitates early detection of various eye conditions, thereby enhancing the quality of eye health care and positively impacting the lives of patients.

The exclusive distribution agreement with EssilorLuxottica, set for an initial term of three years with the possibility of renewal, exemplifies the enduring commitment of both companies to advancing eye health and cutting-edge technology. As per the agreement, Diagnos will be paid on a per-patient-exam basis throughout EssilorLuxottica's network of clients.

Andre Larente, president of Diagnos, expressed his pride, stating: "We are honoured to partner with EssilorLuxottica, a key player in the vision health industry. This agreement marks a pivotal moment in our mission to make our retinal analysis technology accessible to a broader audience, contributing to the visual health of patients in Canada, USA and beyond."

Diagnos and EssilorLuxottica are poised to collaborate closely, offering innovative solutions to optometrists that will revolutionize the early detection of eye problems and elevate the quality of eye care in the region under the agreement.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence platform. Flaire allows for quick modifying and developing of applications such as Cara (computer-assisted retina analysis). Cara's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. Cara is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.